Effects of prolintane on 3,4-dihydroxyphenylacetic acid concentration in rat brain after spiperone treatment.
Prolintane (1-[alpha-propylphenethyl]-pyrrolidine) but not l-(alpha-methylphenethyl)-pyrrolidine markedly enhanced the increase in 3,4-dihydroxyphenylacetic acid concentration in the brains of rats treated with spiperone, a neuroleptic drug. This action and other properties of prolintane described in the literature place it in a group of stimulant drugs that includes methylphenidate, cocaine and amfonelic acid with properties that differ from those of amphetamine.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002090:Butyrophenones / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D008297:Male; D010648:Phenylacetates / Q000378:metabolism*; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013134:Spiperone / Q000494:pharmacology*; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
D002090:Butyrophenones; D010648:Phenylacetates; D011759:Pyrrolidines; D015102:3,4-Dihydroxyphenylacetic Acid; D013134:Spiperone; D012110:Reserpine; C005598:prolintane; D004298:Dopamine